Budros Ruhlin & Roe Inc. Buys 381 Shares of Johnson & Johnson (JNJ)

Budros Ruhlin & Roe Inc. grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,175 shares of the company’s stock after purchasing an additional 381 shares during the quarter. Budros Ruhlin & Roe Inc.’s holdings in Johnson & Johnson were worth $949,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. OLD Point Trust & Financial Services N A lifted its stake in shares of Johnson & Johnson by 2.2% during the second quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock worth $8,113,000 after purchasing an additional 1,321 shares in the last quarter. Lynch & Associates IN lifted its stake in shares of Johnson & Johnson by 0.9% during the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock worth $12,397,000 after purchasing an additional 841 shares in the last quarter. Welch & Forbes LLC lifted its stake in shares of Johnson & Johnson by 0.9% during the second quarter. Welch & Forbes LLC now owns 718,331 shares of the company’s stock worth $95,028,000 after purchasing an additional 6,730 shares in the last quarter. Oakbrook Investments LLC increased its position in shares of Johnson & Johnson by 7.4% during the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock worth $18,008,000 after acquiring an additional 9,375 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its position in shares of Johnson & Johnson by 0.5% during the second quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock worth $102,110,000 after acquiring an additional 3,533 shares during the last quarter. Institutional investors own 65.90% of the company’s stock.

Shares of Johnson & Johnson (NYSE:JNJ) traded up $1.40 during trading on Wednesday, reaching $141.07. The company had a trading volume of 1,120,404 shares, compared to its average volume of 5,877,685. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. The company has a market capitalization of $373,453.13, a price-to-earnings ratio of 19.47, a P/E/G ratio of 2.83 and a beta of 0.80. Johnson & Johnson has a 1 year low of $109.32 and a 1 year high of $144.35.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.68 earnings per share. equities analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.38%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

A number of analysts have recently issued reports on the company. J P Morgan Chase & Co lifted their target price on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 16th. Jefferies Group set a $145.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a research report on Tuesday, August 15th. Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price on the stock. in a research report on Monday, September 18th. Stifel Nicolaus lifted their target price on Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a research report on Wednesday, October 18th. Finally, Citigroup lifted their target price on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company. Johnson & Johnson has an average rating of “Hold” and a consensus target price of $144.59.

TRADEMARK VIOLATION WARNING: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.com-unik.info/2017/12/06/budros-ruhlin-roe-inc-buys-381-shares-of-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit